Immunotherapy Drugs Market

The immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, with a CAGR of 15.3%. Growing demand for personalized medicines and targeted therapies is expected to drive the market growth. Personalized medicine aims to customize treatments for individual patients based on their genetic makeup, disease characteristics, and other factors. Immunotherapy drugs offer a precise & targeted approach to therapy, aligning with the principles of personalized medicine.

The immunotherapy drugs market is a competitive market, with Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland) emerging as top three players in the market. While Pfizer Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), Amgen Inc. (US), Gilead Sciences, Inc. (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd (Israel), GSK PLC (US), and Abbvie Inc. (US) are some of the other prominent players in the market.

To know about the assumptions considered for the study download the pdf brochure

Merck & Co. Inc (US) demonstrates a robust pipeline of immunotherapeutic drugs, leveraging cutting-edge biotechnologies. The company’s expertise in therapeutic areas such as oncology, immunology, and infectious diseases allows for the development of impactful immunotherapy drugs, which are supported by a strong commitment to research excellence and strategic collaborations. It strategically focuses on several key initiatives in immunotherapy drugs. The company prioritizes targeted acquisitions and collaborations to bolster its immunotherapy drugs pipeline, which is exemplified by partnerships with AstraZeneca plc. (UK) and Eisai Co., Ltd. (Japan) for cancer immunotherapy. Also, Merck emphasizes therapeutic innovation, evidenced by the development of groundbreaking immunotherapy drugs such as KEYTRUDA for cancer treatment.

Johnson & Johnson Services, Inc. (US) provides a wide range of immunotherapy drugs and has many immunotherapy drugs approved by central regulatory authorities, such as the FDA and EC. The company has a strong geographical presence coupled with a renowned brand name alongside distributors worldwide, which is a crucial strength of the firm. Their strengths lie in developing innovative Immunotherapy Drugs across various therapeutic areas, ensuring rigorous quality standards, and leveraging strategic partnerships for enhanced research and market access, enabling them to address diverse medical needs effectively. J&J strategically focuses on several key initiatives in Immunotherapy Drugs. The company prioritizes a diversified immunotherapy drugs portfolio, spanning therapeutic areas such as oncology, immunology, and infectious diseases, reducing reliance on any single drug.

F. Hoffmann-La Roche Ltd (Switzerland) provides an extensive range of Immunotherapy Drugs for end users, such as hospitals and specialty care centers. The company has several Immunotherapy Drug products approved by central regulatory authorities, such as the FDA and EC. Additionally, it has a strong geographical presence worldwide with global distribution channels. Their strengths lie in pioneering innovative Immunotherapy Drugs, ensuring rigorous quality control, fostering collaborations, and possessing a deep understanding of disease biology, allowing them to develop transformative treatments and improve patient outcomes. The company recently launched the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer in February 2023.

Other players representing a comparatively smaller revenue share of the market include Immunocore Holdings PLC (UK), Astellas Pharma Inc. (Japan), Genmab A/S (Denmark), Ferring BV (Switzerland), Y-mAbs Therapeutics, Inc. (US), Biogen (US), Kyowa Kirin Co., Ltd. (Japan), Macrogenics, Inc. (US), Swedish Orphan Biovitrum AB (Sweden), and Boehringer Ingelheim International GmbH (Germany).

Related Reports:

Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]